Trial Profile
Impact of Gilenya on Cognitive Function and Thalamic Volume Measured by 7 Tesla MRI in Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 02 Sep 2021 Status changed from active, no longer recruiting to completed.
- 02 Sep 2020 Planned End Date changed from 1 May 2020 to 1 May 2021.
- 18 Nov 2019 Planned End Date changed from 1 Dec 2019 to 1 May 2020.